309 results on '"Daskivich, Timothy J."'
Search Results
2. Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy
3. Patient Perceptions of Standardized Risk Language Used in ACR Prostate MRI PI-RADS Scores
4. Malpractice Trends Involving Active Surveillance Across Cancers
5. Prostate cancer extracellular vesicle digital scoring assay – a rapid noninvasive approach for quantification of disease-relevant mRNAs
6. Variation in content discussed by specialty in consultations for clinically localized prostate cancer
7. Overtreatment of Prostate Cancer Among Men With Limited Longevity in the Active Surveillance Era.
8. Lifestyle and sociodemographic factors associated with treatment choice of clinically localized prostate cancer in an equal access healthcare system
9. Contemporary risk of biochemical recurrence after radical prostatectomy in the active surveillance era
10. Using an Automated Electronic Health Record Score To Estimate Life Expectancy In Men Diagnosed With Prostate Cancer In The Veterans Health Administration
11. Patient- and tumor-level risk factors for MRI-invisible prostate cancer
12. PD61-01 SPECIALTY BIAS IN REPORTING OF ADVANTAGES AND DISADVANTAGES OF TREATMENT OPTIONS IN CONSULTATIONS FOR EARLY STAGE PROSTATE CANCER
13. MP12-13 WHAT WOULD YOU DO IF IT WERE YOU, DOC?: PATIENT AND PHYSICIAN PERSPECTIVES ON WHY PROSTATE CANCER PATIENTS SEEK “PERSONAL ADVICE” FROM PROVIDERS AND HOW PHYSICIANS RESPOND
14. PD13-03 OVERTREATMENT OF MEN WITH LIMITED LIFE EXPECTANCY FOR EARLY STAGE PROSTATE CANCER HAS INCREASED IN THE ACTIVE SURVEILLANCE ERA
15. MP24-01 INTEGRATING NATURAL LANGUAGE PROCESSING WITH CHATGPT TO IMPROVE QUALITY OF ARTIFICIAL INTELLIGENCE SUMMARIES OF PROSTATE CANCER CONSULTATIONS
16. PD62-05 PATIENT PERCEPTIONS OF STANDARDIZED RISK LANGUAGE USED IN AMERICAN COLLEGE OF RADIOLOGY PROSTATE MRI PIRADS SCORES
17. MP68-20 PREDICTION OF LIFE EXPECTANCY USING THE PROSTATE CANCER COMORBIDITY INDEX IN A LARGE, NATIONALLY REPRESENTATIVE COHORT OF MEN WITH PROSTATE CANCER
18. FIGURE 2 from High-resolution Diffusion-weighted Imaging to Detect Changes in Tumor Size and ADC, and Predict Adverse Biopsy Histology during Prostate Cancer Active Surveillance
19. TABLE 1 from High-resolution Diffusion-weighted Imaging to Detect Changes in Tumor Size and ADC, and Predict Adverse Biopsy Histology during Prostate Cancer Active Surveillance
20. TABLE 2 from High-resolution Diffusion-weighted Imaging to Detect Changes in Tumor Size and ADC, and Predict Adverse Biopsy Histology during Prostate Cancer Active Surveillance
21. High-resolution Diffusion-weighted Imaging to Detect Changes in Tumor Size and ADC, and Predict Adverse Biopsy Histology during Prostate Cancer Active Surveillance
22. Supplementary Tables S1, S2 from High-resolution Diffusion-weighted Imaging to Detect Changes in Tumor Size and ADC, and Predict Adverse Biopsy Histology during Prostate Cancer Active Surveillance
23. TABLE 4 from High-resolution Diffusion-weighted Imaging to Detect Changes in Tumor Size and ADC, and Predict Adverse Biopsy Histology during Prostate Cancer Active Surveillance
24. Data from High-resolution Diffusion-weighted Imaging to Detect Changes in Tumor Size and ADC, and Predict Adverse Biopsy Histology during Prostate Cancer Active Surveillance
25. TABLE 3 from High-resolution Diffusion-weighted Imaging to Detect Changes in Tumor Size and ADC, and Predict Adverse Biopsy Histology during Prostate Cancer Active Surveillance
26. Patient function, long‐term survival, and use of surgery in patients with kidney cancer
27. The impact of life expectancy on cost-effectiveness of treatment options for clinically localized prostate cancer
28. Development and Validation of an Improved Pathological Nodal Staging System for Urothelial Carcinoma of the Bladder
29. Disparities in COVID-19 Disease Incidence by Income and Vaccination Coverage--81 Communities, Los Angeles, California, July 2020-September 2021
30. Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics
31. Quality of diagnostic staging in patients with bladder cancer: A process‐outcomes link
32. Use of Persuasive Language in Communication of Risk during Prostate Cancer Treatment Consultations
33. Potential miscommunication of risk in American College of Radiology Prostate Imaging and Data System (PIRADS) scores
34. Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies
35. Androgen deprivation therapy and acute kidney injury in prostate cancer: room for debate?
36. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer
37. Predictors of disparity between targeted and in-zone systematic cores during transrectal MR/US-fusion prostate biopsy
38. Next-generation imaging in localized high-risk prostate cancer
39. Use of Bladder Sparing Surgery for Muscle Invasive Bladder Cancer by Life Expectancy at Diagnosis
40. Limitations of the National Comprehensive Cancer Network® (NCCN®) Guidelines for Prediction of Limited Life Expectancy in Men with Prostate Cancer
41. ProPublica's Surgeon Scorecard: The Argument for Incorporating Appropriateness of Case Selection Into Surgeon Performance Assessment
42. Life Expectancy and Variation in Treatment for Early Stage Kidney Cancer
43. Questioning the 10-year Life Expectancy Rule for High-grade Prostate Cancer: Comparative Effectiveness of Aggressive vs Nonaggressive Treatment of High-grade Disease in Older Men With Differing Comorbid Disease Burdens
44. Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration
45. MP38-01 PATIENT-LEVEL VALIDATION OF LIFE EXPECTANCY CUTOFFS FOR TRIAGE OF AGGRESSIVE TREATMENT BY TUMOR RISK USING TARGETED CROWDSOURCING
46. MP06-06 SINGLE-USE PLASTIC WASTE IN COMMON ENDOUROLOGIC CASES: CHARACTERIZATION OF A GROWING ENVIRONMENTAL CRISIS AND IMPACT OF POSSIBLE INTERVENTIONS
47. MP54-02 VARIATION IN CONTENT DISCUSSED BY SPECIALTY IN CONSULTATIONS FOR CLINICALLY LOCALIZED PROSTATE CANCER
48. PD21-07 RACIAL IMPACT (ASIAN VS. WHITE) ON THE PROGNOSIS OF PATIENTS WITH DE NOVO MCSPC: AN ANALYSIS ON LATITUDE, SEER AND NCDB
49. MP19-11 RACIAL AND ETHNIC DISPARITIES IN VALUATION OF LIFE EXPECTANCY IN PROSTATE CANCER TREATMENT DECISION MAKING
50. An Age Adjusted Comorbidity Index to Predict Long-Term, Other Cause Mortality in Men with Prostate Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.